Top Suppliers:I want be here
Related CAS#:
1231929-97-7 1231930-82-7
1231930-57-6 1158522-08-7
940364-43-2 134104-43-1
131615-57-1 6906-52-1
405141-78-8 930439-75-1
1779839-89-2 1018584-77-4
1375289-11-4

1231929-97-7

1231929-97-7 structure
1231929-97-7 structure
  • Name: Abemaciclib
  • Chemical Name: N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
  • CAS Number: 1231929-97-7
  • Molecular Formula: C27H32F2N8
  • Molecular Weight: 506.593
  • Catalog: Research Areas Cancer
  • Create Date: 2018-03-17 08:00:00
  • Modify Date: 2024-01-02 15:46:50
  • Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
Name N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
Synonyms Abemaciclib
2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-
UNII-60UAB198HK
2-Pyrimidinamine,N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]
N-{5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl}-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzimidazol-6-yl)-2-pyrimidinamine
LY2835219
[5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine
CS-1230
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine
Description Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
Related Catalog
Target

Cdk4/cyclin D1:2 nM (IC50)

CDK6/cyclinD1:10 nM (IC50)

CDK9/cyclinT1:57 nM (IC50)

CDK5/p35:287 nM (IC50)

Cdk5/p25:355 nM (IC50)

CDK2/cyclinE:504 nM (IC50)

CDK7/Mat1/cyclinH1:3910 nM (IC50)

CDK1/cyclinB1:1627 nM (IC50)

PIM1:50 nM (IC50)

PIM2:3400 nM (IC50)

HIPK2:31 nM (IC50)

DYRK2:61 nM (IC50)

CK2:117 nM (IC50)

GSK3b:192 nM (IC50)

JNK3:389 nM (IC50)

FLT3 (D835Y):403 nM (IC50)

FLT3:3960 nM (IC50)

DRAK1:659 nM (IC50)

In Vitro Abemaciclib reduces cell viability with the IC50 values ranging from 0.5 μM to 0.7 μM, inhibits Akt and ERK signaling but not mTOR activation at head and neck squamous cell carcinoma (HNSCC) cells[1]. Abemaciclib shows inhibition on A375R1-4, M14R, and SH4R with EC50 values ranging from 0.3 to 0.6 μM; Abemaciclib inhibits the proliferation of the parental A375 and resistant A375RV1 and A375RV2 cells with similar potencies with IC50 values of 395, 260, and 463 nM, respectively[2]. Abemaciclib inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells[3].
In Vivo Abemaciclib (45 mg/kg, p.o.) in combination with everolimus causes a cooperative antitumor effect in HNSCC xenograft tumor[1]. Abemaciclib (45 or 90 mg/kg, p.o.) shows significant tumor growth inhibition in an A375 xenograft model[2].
Cell Assay Cells are seeded in a 96-well plate, allowed to adhere overnight, and treated with DMSO control (0.1% v/v) or the indicated compounds for 72 h. Cell viability and proliferation are determined using a Cell Counting Kit according to the manufacturer's instructions. The interaction between Abemaciclib and mTOR inhibitor is determined using CompuSyn. Combination index (CI) values of 1 indicates and additive drug interaction, whereas a CI of <1 is synergistic and a CI of >1 is antagonistic.
Animal Admin Six-week-old BALB/c female nude mice are injected subcutaneously with OSC-19 (1×106) cells. When tumor sizes reach approximately 100 mm3, mice are randomized by tumor size and subjected to each treatment. At least 5 mice per treatment group are included. Each group of mice is dosed via daily oral gavage with vehicle, Abemaciclib (45 mg/kg/d or 90 mg/kg/d), Everolimus (5 mg/kg/d), or a combination of both. The Abemaciclib is dissolved in 1% HEC in 20 mM phosphate buffer (pH2.0). Tumor size and body weight are measured twice weekly. Tumor volumes are calculated using the following formula: V=(L×W2)/2. Mice are gavaged a final time on day 14 and sacrificed the following day. The tumors are removed for Western blot and immunohistochemistry.
References

[1]. Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7(12):14803-13.

[2]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.

[3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37.
Density 1.3±0.1 g/cm3
Boiling Point 689.3±65.0 °C at 760 mmHg
Molecular Formula C27H32F2N8
Molecular Weight 506.593
Flash Point 370.7±34.3 °C
Exact Mass 506.271790
PSA 75.00000
LogP 2.74
Vapour Pressure 0.0±2.2 mmHg at 25°C
Index of Refraction 1.656
Hazard Codes Xi
1180132-17-5 structure

1180132-17-5

1231930-42-9 structure

1231930-42-9

~%

1231929-97-7 structure

1231929-97-7

Literature: COATES, David A.; GELBERT, Lawrence Mark; KNOBELOCH, John M.; DE DIOS MAGANA, Alfonso; DE PRADO GONZALEZ, Ana; FILADELFA DEL PRADO CATALINA, Miriam; GARCIA PAREDES, Maria Cristina; MARTIN DE LA NAVA, Eva Maria; MARTIN ORTEGA FINGER, Maria Dolores; MARTINEZ PEREZ, Jose Antonio; MATEO HERRANZ, Ana Isabel; PEREZ MARTINEZ, Carlos; SANCHEZ MARTINEZ, Concepcion Patent: US2010/160340 A1, 2010 ; Location in patent: Page/Page column 14 ;
Precursor  1

DownStream  0


Chemsrc provides CAS#:1231929-97-7 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1231929-97-7 | Chemsrc address: https://www.chemsrc.com/en/baike/1042892.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved